Impact of complete cytogenetic response on survival in patients with myelodysplastic syndromes.

被引：0
|
作者：
Urrutia, Samuel
Sasaki, Koji
Kantarjian, Hagop M.
Jabbour, Elias
Chien, Kelly Sharon
Hammond, Danielle
Bueso-Ramos, Carlos E.
Khoury, Joseph
Patel, Keyur P.
Montalban-Bravo, Guillermo
Wei, Yue
Colla, Simona
Short, Nicholas James
Daver, Naval Guastad
Borthakur, Gautam
Kadia, Tapan M.
Pierce, Sherry
Wierda, William G.
Garcia-Manero, Guillermo
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6567
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Iron overload and myelodysplastic syndromes.
    Rose, C
    Cambier, N
    Mahieu, M
    Ernst, O
    Fenaux, P
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2001, 8 (05) : 422 - 432
  • [42] Positive Impact of T-Cell Clonal Expansion On Overall Survival in Patients with High-Risk Myelodysplastic Syndromes.
    Schmidt, Amber
    Komrokji, Rami S.
    Painter, Jeffrey S.
    Rollison, Dana E.
    Zhang, Ling
    Moscinski, Lynn C.
    List, Alan F.
    Epling-Burnette, P. K.
    BLOOD, 2009, 114 (22) : 629 - 629
  • [43] Microvascular density in bone marrow of patients with myelodysplastic syndromes.
    Machhi, J
    Bunyi-Teopengco, E
    Chang, C
    Shidham, VB
    Wang, G
    Kampalath, B
    MODERN PATHOLOGY, 2001, 14 (01) : 171A - 171A
  • [44] Endogenous serum thrombopoietin levels in patients with myelodysplastic syndromes.
    Zwierzina, H
    RollingerHolzinger, I
    Herold, M
    Nuessler, V
    Meng, YG
    BLOOD, 1995, 86 (10) : 1330 - 1330
  • [45] Systemic diseases in myelodysplastic syndromes.
    Hebbar, M
    HebbarSavean, K
    Fenaux, P
    REVUE DE MEDECINE INTERNE, 1995, 16 (12): : 897 - 904
  • [46] Cyclosporine a without or with thalidomide for the treatment of patients with Myelodysplastic syndromes.
    Xiao, Zhijian
    Xu, Zefeng
    Wang, Jianxiang
    Hao, Yushu
    BLOOD, 2007, 110 (11) : 222B - 222B
  • [47] Impact of immunophenotype on prognosis of patients with myelodysplastic syndromes.: Its value in patients without karyotypic abnormalities
    Arroyo, JL
    Fernández, ME
    Hernández, JIM
    Orfao, A
    San Miguel, JF
    del Cañizo, MC
    HEMATOLOGY JOURNAL, 2004, 5 (03) : 227 - 233
  • [48] Economic burden of transfusion dependence in patients with myelodysplastic syndromes.
    Frytak, JR
    Henk, H
    Nelson, M
    Decastro, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 544S - 544S
  • [49] Microvascular density in bone marrow of patients with myelodysplastic syndromes.
    Machhi, J
    Bunyi-Teopengco, E
    Chang, C
    Shidham, VB
    Wang, G
    Kampalath, B
    LABORATORY INVESTIGATION, 2001, 81 (01) : 171A - 171A
  • [50] Abnormalities in the expression of cytokines and their receptors in patients with myelodysplastic syndromes.
    FontenayRoupie, M
    Dreyfus, F
    PATHOLOGIE BIOLOGIE, 1997, 45 (07): : 569 - 572
12345